By Justin Petrone

Harvard spinout Ligon Discovery will work with pharmaceutical maker Lycera to identify first-in-class drug candidates for immune disorders, the company said last week.

Under the terms of the deal, Cambridge, Mass.-based Ligon will use its small-molecule microarray, or SMM, platform to screen protein targets that Lycera believes are critical to the development of certain immune disorders.

Financial terms of the pact were not discussed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.